Education
About Us
Working with TipRanks
Follow Us
Immuron Ltd (IMRN)
NASDAQ:IMRN
IMRN Stock Chart & Stats
$0.82
-$0.03(-1.20%)
At close: 4:00 PM EST
$0.82
-$0.03(-1.20%)
Day’s Range― - ―
52-Week Range$0.68 - $2.39
Previous CloseN/A
Volume5.19K
Average Volume (3M)75.95K
Market Cap
$7.80M
Enterprise Value$6.35M
Total Cash (Recent Filing)$5.87M
Total Debt (Recent Filing)$117.13K
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Mar 04, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding8,166,340
10 Day Avg. Volume112,552
30 Day Avg. Volume75,952
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.90
Price to Sales (P/S)2.09
P/FCF Ratio-2.49
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue0.58
Enterprise Value/Gross Profit0.89
Enterprise Value/Ebitda-0.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product-driven Revenue GrowthSubstantial FY2025 sales growth, led by Travelan®, indicates scalable commercial traction and growing consumer demand. Durable revenue expansion in key markets strengthens the company's ability to fund operations and R&D over the next several quarters and supports distribution scale-up.
Conservative Capital StructureExtremely low leverage reduces solvency risk and preserves financial flexibility. With minimal debt obligations, Immuron has structural capacity to raise incremental capital or redirect cash to clinical programs without near-term fixed financing burdens, improving resilience.
Clinical And Regulatory ProgressIND approval and planned Phase 2 for IMM-529 materially advance the pipeline and de-risk future value creation pathways. Regulatory progress and successful Travelan trials strengthen development credibility, improving prospects for partnerships and longer-term commercial opportunities.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flows imply ongoing cash burn that will pressure the balance sheet and necessitate external financing. This structural cash deficit constrains R&D and commercialization investments until cash generation is restored or new funding is secured.
Persistent Unprofitability And Weak MarginsDeeply negative net and operating margins indicate the business is not yet converting gross profitability into positive operating results. Unless structural cost or revenue dynamics change, losses will persist and limit internal funding for growth and long-term sustainability.
Very Small Operating ScaleAn extremely small headcount limits internal capacity for clinical development, regulatory management, and commercial execution. Reliance on partners or contractors increases execution risk and may slow timelines for trials, approvals, and market expansion over coming months.
Immuron News
IMRN FAQ
What was Immuron Ltd’s price range in the past 12 months?
Immuron Ltd lowest stock price was $0.68 and its highest was $2.39 in the past 12 months.
What is Immuron Ltd’s market cap?
Immuron Ltd’s market cap is $7.80M.
When is Immuron Ltd’s upcoming earnings report date?
Immuron Ltd’s upcoming earnings report date is Mar 04, 2026 which is in 27 days.
How were Immuron Ltd’s earnings last quarter?
Immuron Ltd released its earnings results on Aug 28, 2025. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.007.
Is Immuron Ltd overvalued?
According to Wall Street analysts Immuron Ltd’s price is currently Overvalued.
Does Immuron Ltd pay dividends?
Immuron Ltd does not currently pay dividends.
What is Immuron Ltd’s EPS estimate?
Immuron Ltd’s EPS estimate is >-0.01.
How many shares outstanding does Immuron Ltd have?
Immuron Ltd has 8,166,340 shares outstanding.
What happened to Immuron Ltd’s price movement after its last earnings report?
Immuron Ltd reported an EPS of -$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.549%.
Which hedge fund is a major shareholder of Immuron Ltd?
Currently, no hedge funds are holding shares in IMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuron Ltd
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---